Dr Reddys Laboratories Stock Fundamentals

RDY Stock  USD 73.35  1.04  1.44%   
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 116.3 B in 2024, whereas Cost Of Revenue is likely to drop slightly above 44.3 B in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RDY Total Asset Analysis

Dr Reddys' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
 2021 2022 2023 2024 (projected)
Other Current Liabilities41.6B48.9B56.2B59.0B
Total Assets296.7B322.9B371.3B206.1B

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Dr Reddys Total Asset

    
  322.85 B  
Most of Dr Reddys' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

RDY Total Asset Historical Pattern

Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dr Reddys total asset as a starting point in their analysis.
   Dr Reddys Total Asset   
       Timeline  
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

RDY Total Assets

Total Assets

206.07 Billion

At this time, Dr Reddys' Total Assets are fairly stable compared to the past year.
Based on the latest financial disclosure, Dr Reddys Laboratories has a Total Asset of 322.85 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is significantly lower than that of the firm.

Dr Reddys Laboratories Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.
Dr Reddys Laboratories is currently regarded as top stock in retained earnings category among related companies. It is currently regarded as top stock in current asset category among related companies fabricating about  0.01  of Current Asset per Retained Earnings. The ratio of Retained Earnings to Current Asset for Dr Reddys Laboratories is roughly  119.31 . At this time, Dr Reddys' Retained Earnings are fairly stable compared to the past year.. Comparative valuation analysis is a catch-all model that can be used if you cannot value Dr Reddys by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dr Reddys' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.

RDY Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.
Dr Reddys is currently under evaluation in return on equity category among related companies.

RDY Fundamentals

About Dr Reddys Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Current Deferred Revenue1.8 B1.7 B
Total Revenue282.8 B296.9 B
Cost Of Revenue49.3 B44.3 B
Ebit Per Revenue 0.35  0.37 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dr Reddys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dr Reddys' short interest history, or implied volatility extrapolated from Dr Reddys options trading.

Currently Active Assets on Macroaxis

When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis.
Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for RDY Stock analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.103
Dividend Share
40
Earnings Share
3.75
Revenue Per Share
272.4618
Quarterly Revenue Growth
0.066
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.